Somewhat Positive News Coverage Somewhat Unlikely to Impact Jazz Pharmaceuticals (JAZZ) Stock Price
News articles about Jazz Pharmaceuticals (NASDAQ:JAZZ) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 45.89305147579 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Gov’t, Johnson & Johnson to accelerate Cancer Control Strategy dissemination efforts (kbc.co.ke)
- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide (reuters.com)
- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease (finance.yahoo.com)
- Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect? – Nasdaq (nasdaq.com)
Shares of Jazz Pharmaceuticals (JAZZ) traded up $3.04 during trading hours on Friday, hitting $147.46. 251,344 shares of the company’s stock were exchanged, compared to its average volume of 424,981. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $163.75. The stock has a market cap of $8,660.00, a PE ratio of 24.29, a P/E/G ratio of 0.75 and a beta of 0.99. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.
In other news, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.15, for a total value of $27,830.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 9,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $139.73, for a total transaction of $1,257,570.00. The disclosure for this sale can be found here. Insiders have sold a total of 13,300 shares of company stock valued at $1,899,640 in the last quarter. 4.30% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-jazz-pharmaceuticals-jazz-stock-price/1886150.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.